‘Stivarga Tab’ settled by RSA, becoming the 10th

The risk sharing agreement(RSA) for Stivarga Tab, a Bayer’s regorafenib gastrointestinal tumor treatment was settled. Thus, it became the 10^th RSA-applied drug, starting with Evoltra Inj on December 2013.

The National Health Insurance Service(NHIS) and Bayer settled the RSA for Stivarga Tab. The type is, of course, the refund type.

The Ministry of Health and Welfare will introduce an action t...